It's Unlikely That Shareholders Will Increase Genus plc's (LON:GNS) Compensation By Much This Year
Nov 17
U.K. (FTSE) Biotech Industry Analysis
UpdatedNov 29, 2022
DataAggregated Company Financials
Companies32
- 7D4.1%
- 3M12.1%
- 1Y-32.3%
- YTD-29.8%
The Biotech industry is up 4.1% in the last week, with Scancell Holdings up 27%. Meanwhile, Genus actually underperformed within the industry, shrinking 6.6% in the last week. In the past year, the industry is down 32%. Looking forward, earnings are forecast to grow by 25% annually.
Industry Valuation and Performance
Has the U.K. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 30 Nov 2022 | UK£8.1b | UK£1.2b | -UK£139,491,980.00 | 24.4x | -58x | 7x |
| Fri, 28 Oct 2022 | UK£7.3b | UK£1.2b | -UK£148,574,600.00 | 22.9x | -48.9x | 6.3x |
| Sun, 25 Sep 2022 | UK£7.2b | UK£1.2b | -UK£174,838,754.00 | 26.4x | -41.3x | 6.2x |
| Tue, 23 Aug 2022 | UK£7.5b | UK£1.1b | -UK£203,421,153.00 | 36.6x | -36.7x | 6.7x |
| Thu, 21 Jul 2022 | UK£7.0b | UK£1.1b | -UK£202,133,604.00 | 35.2x | -34.5x | 6.3x |
| Sat, 18 Jun 2022 | UK£6.6b | UK£1.1b | -UK£159,017,173.00 | 36.1x | -41.8x | 6x |
| Mon, 16 May 2022 | UK£6.9b | UK£1.1b | -UK£146,427,737.00 | 36.6x | -47.1x | 6.2x |
| Wed, 13 Apr 2022 | UK£7.6b | UK£1.1b | -UK£91,924,862.00 | 40.5x | -82.5x | 7x |
| Fri, 11 Mar 2022 | UK£7.5b | UK£1.1b | -UK£134,929,617.00 | 31.9x | -55.6x | 6.9x |
| Sun, 06 Feb 2022 | UK£8.9b | UK£1.1b | -UK£119,969,127.00 | 38.6x | -74.3x | 8.2x |
| Tue, 04 Jan 2022 | UK£11.5b | UK£1.1b | -UK£120,793,971.00 | 57.3x | -94.9x | 10.6x |
| Thu, 02 Dec 2021 | UK£11.2b | UK£1.1b | -UK£121,397,789.00 | 61.4x | -92.2x | 10.3x |
| Sat, 30 Oct 2021 | UK£11.7b | UK£1.1b | -UK£136,297,738.00 | 70.8x | -86x | 10.8x |
| Mon, 27 Sep 2021 | UK£12.3b | UK£1.1b | -UK£127,246,067.00 | 69.7x | -96.3x | 11.1x |
| Wed, 25 Aug 2021 | UK£12.5b | UK£1.0b | -UK£172,541,949.91 | 31.1x | -72.4x | 12.2x |
| Thu, 01 Jul 2021 | UK£11.2b | UK£1.0b | -UK£172,541,949.91 | 30.1x | -65x | 11x |
| Sun, 04 Apr 2021 | UK£10.8b | UK£1.0b | -UK£166,311,048.52 | 31.3x | -65x | 10.6x |
| Wed, 06 Jan 2021 | UK£9.7b | UK£1.0b | -UK£143,856,708.81 | 33.2x | -67.1x | 9.6x |
| Sat, 10 Oct 2020 | UK£8.1b | UK£985.1m | -UK£118,992,987.81 | 56.2x | -68.1x | 8.2x |
| Fri, 03 Jul 2020 | UK£7.5b | UK£992.9m | -UK£137,441,757.45 | 56.4x | -54.9x | 7.6x |
| Mon, 06 Apr 2020 | UK£6.2b | UK£985.7m | -UK£113,867,379.81 | 53.2x | -54.1x | 6.2x |
| Thu, 09 Jan 2020 | UK£6.3b | UK£946.8m | -UK£64,026,720.44 | 53.1x | -98.9x | 6.7x |
Price to Earnings Ratio
-75.7x
Current Industry PE
- Investors are pessimistic on the British Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 9.0x is higher than the industry's current PS ratio of 7.0x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 7.8% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Trends
Which industries have driven the changes within the U.K. Healthcare industry?
| GB Market | 1.10% | |
| Healthcare | 0.038% | |
| Biotech | 4.06% | |
| Biotech | 4.06% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| SCLP Scancell Holdings | UK£0.23 | 27.4% +UK£40.8m | 14.8% | PB10.5x | |
| FARN Faron Pharmaceuticals Oy | UK£2.73 | 23.9% +UK£31.4m | -12.1% | PE-7.9x | |
| PRTC PureTech Health | UK£2.72 | 2.8% +UK£20.9m | -7.0% | PS48.7x | |
| AVCT Avacta Group | UK£1.17 | 5.7% +UK£16.3m | 0.9% | PS43.7x | |
| OXB Oxford Biomedica | UK£3.70 | 3.6% +UK£12.5m | -71.9% | PS2.8x |
